» Authors » Manon C W Spaander

Manon C W Spaander

Explore the profile of Manon C W Spaander including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 222
Citations 2575
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Katsara M, van den Berg D, Spaander M, van Vuuren A, Dekker E, van Kemenade F, et al.
Int J Cancer . 2025 Mar; PMID: 40079681
This study investigates the impact of extended invitation intervals on the stage distribution of screen-detected and interval colorectal cancers (CRCs) in the Netherlands' fecal immunochemical test (FIT)-based screening program during...
2.
3.
Eikenboom E, van Leeuwen L, Groenendijk F, Woolderink J, Van Altena A, van Leerdam M, et al.
EClinicalMedicine . 2025 Jan; 79():103006. PMID: 39816931
Background: Female Lynch syndrome carriers have an increased risk of developing endometrial cancer. Regardless, research on endometrial carcinoma tumorigenesis is scarce and no uniform, evidence-based gynaecological management guidelines exist. We...
4.
Guo X, Lam S, Janmaat V, de Jonge P, Hansen B, Leeuwenburgh I, et al.
JAMA Netw Open . 2025 Jan; 8(1):e2454685. PMID: 39808429
Importance: Patients with achalasia face a higher risk of developing esophageal cancer (EC), but the surveillance strategies for these patients remain controversial due to the long disease duration and the...
5.
van Stigt B, Lansdorp-Vogelaar I, Spaander M, van Vuuren A, Dekker E, van Kemenade F, et al.
Int J Cancer . 2024 Dec; 156(9):1783-1790. PMID: 39697047
Upper age limits are currently fixed for all fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening programs. A risk-stratified upper age limit may be beneficial. Therefore, we assessed differences in...
6.
Eikenboom E, Nasar N, Seier K, Gonen M, Spaander M, OReilly E, et al.
Ann Surg Oncol . 2024 Dec; PMID: 39656390
Background: Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease due to its aggressiveness, late-stage diagnosis, and limited treatment options. Microsatellite instability-high (MSI-H) cancers are susceptible to immune checkpoint inhibitors. Survival...
7.
Mulder D, van de Schootbrugge-Vandermeer H, OMahony J, Sun D, Han W, Verhoeven R, et al.
Cancer Epidemiol Biomarkers Prev . 2024 Nov; 34(1):85-92. PMID: 39526877
Background: Identification of groups at a high risk of gastric cancer could facilitate targeted screening in countries with a low gastric cancer incidence. Our aim was to identify such high-risk...
8.
van Liere E, Ramsoekh D, Daulton E, Dakkak M, van Lingen J, Stewart T, et al.
Aliment Pharmacol Ther . 2024 Oct; 61(1):145-158. PMID: 39422092
Background: Non-invasive biomarkers may reduce post-colonoscopy colorectal cancer (CRC) rates and colonoscopy overuse in Lynch syndrome. Unlike faecal immunochemical test (FIT), faecal volatile organic compounds (VOCs) may accurately detect both...
9.
Toes-Zoutendijk E, van de Schootbrugge-Vandermeer H, Katsara M, de Jonge L, Spaander M, van Vuuren A, et al.
Clin Gastroenterol Hepatol . 2024 Oct; 23(4):653-661.e3. PMID: 39395573
Background And Aims: This study aimed to provide evidence on the harm-to-benefit ratio of fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening by previous fecal hemoglobin (f-Hb) concentrations, as reflected...
10.
Zellenrath P, van Tilburg L, Pouw R, Yadlapati R, Peters Y, Ujiki M, et al.
Clin Gastroenterol Hepatol . 2024 Oct; 23(2):225-235.e8. PMID: 39370089
Background And Aims: Females with Barrett's esophagus (BE) have a lower risk of neoplastic progression than males, but sufficiently powered risk analyses are lacking. This systematic review and meta-analysis of...